What is the share price of Jubilant Pharmova Ltd (JUBLPHARMA) today?
The share price of JUBLPHARMA as on 29th May 2026 is ₹995. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Jubilant Pharmova Ltd (JUBLPHARMA) share?
The past returns of Jubilant Pharmova Ltd (JUBLPHARMA) share are- Past 1 week: -1.97%
- Past 1 month: 4.87%
- Past 3 months: 14.86%
- Past 6 months: -10.25%
- Past 1 year: -13.85%
- Past 3 years: 177.55%
- Past 5 years: 13.90%
What are the peers or stocks similar to Jubilant Pharmova Ltd (JUBLPHARMA)?
The peers or stocks similar to Jubilant Pharmova Ltd (JUBLPHARMA) include:What is the dividend yield % of Jubilant Pharmova Ltd (JUBLPHARMA) share?
The current dividend yield of Jubilant Pharmova Ltd (JUBLPHARMA) is 0.50.What is the market cap of Jubilant Pharmova Ltd (JUBLPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jubilant Pharmova Ltd (JUBLPHARMA) is ₹15759.52 Cr as of 29th May 2026.What is the 52 week high and low of Jubilant Pharmova Ltd (JUBLPHARMA) share?
The 52-week high of Jubilant Pharmova Ltd (JUBLPHARMA) is ₹1248 and the 52-week low is ₹786.05.What is the PE and PB ratio of Jubilant Pharmova Ltd (JUBLPHARMA) stock?
The P/E (price-to-earnings) ratio of Jubilant Pharmova Ltd (JUBLPHARMA) is 39.55. The P/B (price-to-book) ratio is 2.53.Which sector does Jubilant Pharmova Ltd (JUBLPHARMA) belong to?
Jubilant Pharmova Ltd (JUBLPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Jubilant Pharmova Ltd (JUBLPHARMA) shares?
You can directly buy Jubilant Pharmova Ltd (JUBLPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Jubilant Pharmova Ltd
JUBLPHARMA Share Price
NSE₹995.000.33% (+3.25)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
JUBLPHARMA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
JUBLPHARMA Performance & Key Metrics
JUBLPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 39.55 | 2.53 | 0.50% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.84 | 6.22 | 0.48% |
100%
Analysts have suggested that investors can buy this stock
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
JUBLPHARMA Company Profile
Jubilant Life Sciences Limited is a pharmaceutical and life sciences company.
SUNPHARMA
PE Ratio
37.61
37.61
1Y Return
5.85%
5.85%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
69.82
69.82
1Y Return
39.53%
39.53%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.17
29.17
1Y Return
5.14%
5.14%
Buy Reco %
62.86
62.86
DRREDDY
PE Ratio
25.87
25.87
1Y Return
4.43%
4.43%
Buy Reco %
51.52
51.52
ZYDUSLIFE
PE Ratio
21.52
21.52
1Y Return
16.54%
16.54%
Buy Reco %
53.57
53.57
JUBLPHARMA Forecast
JUBLPHARMA Forecasts
Price
Revenue
Earnings
JUBLPHARMA Share Price Forecast
JUBLPHARMA Share Price Forecast
2026
Current
₹995.00
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹995.00
Baseline
Forecast for May 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
JUBLPHARMA Company Revenue Forecast
JUBLPHARMA Company Revenue Forecast
2026
Current
₹8.35
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹8.35
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
JUBLPHARMA Stock EPS (Earnings Per Share) Forecast
JUBLPHARMA Stock EPS (Earnings Per Share) Forecast
2026
Current
₹25.15
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹25.15
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
JUBLPHARMA
JUBLPHARMA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
JUBLPHARMA Income Statement
JUBLPHARMA Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,726.00 | 1,776.40 | 2,141.60 | 1,774.00 | 1,830.90 | 1,940.70 | 1,912.70 | 1,976.20 | 2,143.00 | 2,313.70 | ||||||||||
Operating & Other expenses | 1,459.10 | 1,656.10 | 1,480.20 | 1,477.20 | 1,553.50 | 1,586.80 | 1,611.20 | 1,630.90 | 1,872.80 | 1,964.40 | ||||||||||
EBITDA | 266.90 | 120.30 | 661.40 | 296.80 | 277.40 | 353.90 | 301.50 | 345.30 | 270.20 | 349.30 | ||||||||||
| Depreciation/Amortization | 94.60 | 101.00 | 90.70 | 91.40 | 91.30 | 95.20 | 98.10 | 104.80 | 120.70 | 116.80 | ||||||||||
| PBIT | 172.30 | 19.30 | 570.70 | 205.40 | 186.10 | 258.70 | 203.40 | 240.50 | 149.50 | 232.50 | ||||||||||
| Interest & Other Items | 71.30 | 73.00 | 71.00 | 61.00 | 55.60 | 52.70 | 49.00 | 50.20 | 56.10 | 56.50 | ||||||||||
| PBT | 101.00 | -53.70 | 499.70 | 144.40 | 130.50 | 206.00 | 154.40 | 190.30 | 93.40 | 176.00 | ||||||||||
| Taxes & Other Items | 34.20 | 4.90 | 17.60 | 41.60 | 29.60 | 52.40 | 51.50 | 70.00 | 37.50 | 56.60 | ||||||||||
| Net Income | 66.80 | -58.60 | 482.10 | 102.80 | 100.90 | 153.60 | 102.90 | 120.30 | 55.90 | 119.40 | ||||||||||
| EPS | 4.22 | -3.69 | 30.44 | 6.47 | 6.37 | 9.71 | 6.49 | 7.59 | 3.52 | 7.55 |
JUBLPHARMA Company Updates
FY 2015FY 2015
FY 2014FY 2014
Investor Presentation
Feb 6PDF
JUBLPHARMA Stock Peers
JUBLPHARMA Past Performance & Peer Comparison
JUBLPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Jubilant Pharmova Ltd | 39.55 | 2.53 | 0.50% |
| Sun Pharmaceutical Industries Ltd | 37.61 | 5.96 | 0.89% |
| Torrent Pharmaceuticals Ltd | 69.82 | 19.67 | — |
| Cipla Ltd | 29.17 | 3.62 | 0.93% |
JUBLPHARMA Stock Price Comparison
Compare JUBLPHARMA with any stock or ETFCompare JUBLPHARMA with any stock or ETF
JUBLPHARMA
JUBLPHARMA Holdings
JUBLPHARMA Shareholdings
JUBLPHARMA Promoter Holdings Trend
JUBLPHARMA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
JUBLPHARMA Institutional Holdings Trend
JUBLPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
JUBLPHARMA Shareholding Pattern
JUBLPHARMA Shareholding Pattern
JUBLPHARMA Shareholding History
JUBLPHARMA Shareholding History
Foreign Institutions
Mutual Funds Invested in JUBLPHARMA
Mutual Funds Invested in JUBLPHARMA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Jubilant Pharmova Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.9344% | Percentage of the fund’s portfolio invested in the stock 1.20% | Change in the portfolio weight of the stock over the last 3 months 0.23% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 10/263 (+8) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.7385% | Percentage of the fund’s portfolio invested in the stock 0.90% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/123 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9478% | Percentage of the fund’s portfolio invested in the stock 0.67% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 69/81 (-2) |
Compare 3-month MF holding change on Screener
smallcases containing JUBLPHARMA stock
smallcases containing JUBLPHARMA stock
Looks like this stock is not in any smallcase yet.
JUBLPHARMA Events
JUBLPHARMA Events
JUBLPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
JUBLPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.50%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.04 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
JUBLPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
JUBLPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.50%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.04 every year
JUBLPHARMA Upcoming Dividends
JUBLPHARMA Upcoming Dividends
No upcoming dividends are available
JUBLPHARMA Past Dividends
JUBLPHARMA Past Dividends
Cash Dividend
Ex DateEx DateJul 25, 2025
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Jul 25, 2025
Cash Dividend
Ex DateEx DateAug 2, 2024
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 2, 2024
Cash Dividend
Ex DateEx DateAug 10, 2023
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 10, 2023
Cash Dividend
Ex DateEx DateAug 11, 2022
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 11, 2022
Cash Dividend
Ex DateEx DateAug 5, 2021
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 5, 2021
JUBLPHARMA Stock News & Opinions
JUBLPHARMA Stock News & Opinions
Articles & Videos
Corporate
Corporate
Board of Jubilant Pharmova recommends final dividendJubilant Pharmova announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 500%) , subject to the approval of the shareholders.
1 week agoCapital Market - Live
Earnings
Earnings
Jubilant Pharmova consolidated net profit declines 22.27% in the March 2026 quarterNet profit of Jubilant Pharmova declined 22.27% to Rs 119.40 crore in the quarter ended March 2026 as against Rs 153.60 crore during the previous quarter ended March 2025. Sales rose 18.60% to Rs 2272.20 crore in the quarter ended March 2026 as against Rs 1915.80 crore during the previous quarter ended March 2025. For the full year,net profit declined 52.53% to Rs 398.50 crore in the year ended March 2026 as against Rs 839.40 crore during the previous year ended March 2025. Sales rose 14.36% to Rs 8225.00 crore in the year ended March 2026 as against Rs 7192.10 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2272.201915.80 19 8225.007192.10 14 OPM %14.9318.02 -15.3116.31 - PBDT306.50304.50 1 1113.70989.70 13 PBT189.70209.30 -9 673.30621.10 8 NP119.40153.60 -22 398.50839.40 -53 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Corporate
Jubilant Pharmova fixes record date for final dividendJubilant Pharmova has fixed 24 July 2026 as record date for purpose of final dividend payment of Rs 5 per equity share of Re 1 for FY 2026.
1 week agoCapital Market - Live
Corporate
Corporate
Jubilant Pharmova to convene board meetingJubilant Pharmova will hold a meeting of the Board of Directors of the Company on 22 May 2026.
1 month agoCapital Market - Live
Earnings
Earnings
Jubilant Pharmova consolidated net profit declines 44.60% in the December 2025 quarterNet profit of Jubilant Pharmova declined 44.60% to Rs 55.90 crore in the quarter ended December 2025 as against Rs 100.90 crore during the previous quarter ended December 2024. Sales rose 16.67% to Rs 2116.10 crore in the quarter ended December 2025 as against Rs 1813.70 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales2116.101813.70 17 OPM %13.6815.83 - PBDT253.80240.70 5 PBT133.10149.40 -11 NP55.90100.90 -45 Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Spotlight
Jubilant Pharmova slips after weak Q3 performanceRevenue rose by 17% YoY to Rs 2,123 crore during the quarter. While EBITDA improved by 5% to Rs 310 crore, EBITDA margin declined by 172 basis points to 14.5% in Q3 FY26 as compared with Q3 FY25. Profit before tax in Q3 FY26 stood at Rs 93.4 crore, down by 28% from Rs 130.5 crore recorded in Q3 FY25. Shyam S Bhartia, chairman of Jubilant Pharmova, and Hari S Bhartia, co-chairman & non-executive director of Jubilant Pharmova, said: 'Revenue growth is particularly driven by incremental revenue generation from the new & third line in CDMO Sterile Injectable business. We expect this growth momentum to continue as we make progress in the last quarter of current financial year. As we are consciously investing in Radiopharma, CDMO Sterile Injectables and CRDMO business to secure future growth, Net Debt / EBITDA remains range bound at 1.3x in Dec'25, lower from 1.5x in Sep'25. During Q3'FY26, we saw exceptional growth momentum in the Ruby-Fill installs. In the Allergy Immunotherapy business, we witnessed increase in demand from the US market. In the CDMO Sterile Injectables business, we ramped up revenue generation from technology transfer programs at Line 3 in Spokane. In the CRDMO business, we continue to invest in building CDMO capabilities. In the Generics business, we are foreseeing growth & profitability improvement. Lastly, in our Proprietary Novel drugs business, we continue to make progress in JBI-802 and JBI-778 clinical trials. Jubilant Pharmova is a company with a global presence that is involved in radiopharma, allergy immunotherapy, CDMO sterile injectables, contract research development and manufacturing organisation (CRDMO), generics and proprietary novel drugs businesses. Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Jubilant Pharmova to declare Quarterly ResultsJubilant Pharmova will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Jubilant Pharmova appoints Daniel J. O'Connor as CEO of Jubilant Therapeutics Inc.Jubilant Pharmova has appointed Daniel J. O'Connor as CEO of Jubilant Therapeutics Inc. step down subsidiary of the company. Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Board of Jubilant Pharmova approves grant of 1,506 stock optionsThe board of Jubilant Pharmova at its meeting held on 31 October 2025 has approved the Grant of 1,506 Stock Options/ Restricted Stock Units (RSUs) to the eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Earnings
Jubilant Pharmova consolidated net profit rises 17.02% in the September 2025 quarterNet profit of Jubilant Pharmova rose 17.02% to Rs 120.30 crore in the quarter ended September 2025 as against Rs 102.80 crore during the previous quarter ended September 2024. Sales rose 12.38% to Rs 1957.80 crore in the quarter ended September 2025 as against Rs 1742.20 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1957.801742.20 12 OPM %17.4316.61 - PBDT300.90250.00 20 PBT196.10158.60 24 NP120.30102.80 17 Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 4.18%, vs industry avg of 9.86%
Over the last 5 years, market share decreased from 2.45% to 1.8%
Over the last 5 years, net income has grown at a yearly rate of -1.35%, vs industry avg of 19.71%